OncoMatch/Clinical Trials/NCT05493215

Imatinib TDM in GIST

Is NCT05493215 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Imatinib for gastrointestinal stromal tumors.

Phase 2RecruitingReema A. PatelNCT05493215Data as of May 2026

Treatment: Imatinib — Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastrointestinal Stromal Tumor

Biomarker criteria

Required: KIT mutation

KIT mutation

Required: PDGFRA mutation

PDGFRA mutation (non-D842V)

Excluded: PDGFRA D842V

Presence of PDGFRA D842V mutation

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

normal organ function

Kidney function

normal organ function

Liver function

normal organ function

Normal organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Markey Cancer Center · Lexington, Kentucky

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify